Rocky Hill-based medical technology firm Lumeda, which is developing a lung cancer-killing light therapy system, raised $4.3 million through its Series A funding round and now expects to start human clinical studies by the middle of this year, company officials announced Thursday.
Combined with a seed funding round that took place early last year, Lumeda has raised $5.3 million to date, they said.
The Series A round was led by Connecticut Innovations, the state’s venture investment arm, with participation from Cycle Venture Partners, a Branford-based venture capital group.
The company expects two first-in-human clinical studies to commence at Roswell Park Comprehensive Cancer Center in Buffalo, New York, by mid-2021, and CEO Sandy Zinke said the plan is to “expand testing to other sites in the U.S., Europe and Japan.”
Lumeda’s technology, branded as DigiLum, is a form of photodynamic therapy, which involves introducing a photosensitizer drug to cancer cells that triggers cell death upon light activation.
